Related Experiment Videos
Prostacyclin and prostanoid modifiers aid ischemic skin flap survival
K R Knight1, H Kawabata, S A Coe
1Microsurgery Research Centre, St. Vincent's Hospital, Melbourne, Victoria, Australia.
The Journal of Surgical Research
|February 1, 1991
Summary
Prostacyclin and its analogues, carbacyclin and dipyridamole, significantly improved free flap survival after ischemia in rabbits. Vasodilatory agents enhanced flap survival, while antithrombotic agents alone were insufficient.
Area of Science:
- Vascular Surgery
- Ischemia-Reperfusion Injury
- Pharmacology
Background:
- Ischemia-reperfusion injury remains a significant challenge in free flap survival.
- Vasodilators and antithrombotic agents are potential therapeutic strategies to mitigate this injury.
Purpose of the Study:
- To evaluate the efficacy of prostacyclin, carbacyclin, UK-38,485, and dipyridamole in improving free flap survival following ischemia.
- To determine the correlation between pharmacological properties (vasodilation, antithrombosis) and flap survival.
Main Methods:
- Rabbit epigastric free flaps were subjected to a period of ischemia.
- Flaps were infused with prostacyclin, carbacyclin, UK-38,485, or dipyridamole.
- Flap survival rates were compared to a control group infused with balanced salt solution.
Main Results:
- Prostacyclin, carbacyclin, and dipyridamole significantly increased flap survival rates (68.4%, 66.4%, 66.9% respectively) compared to controls (39.9%).
- UK-38,485 showed a non-significant improvement in survival (47.6%).
- Improved survival correlated with vasodilatory effects, not solely antithrombotic properties.
Conclusions:
- Prostacyclin, carbacyclin, and dipyridamole are effective in improving free flap survival after ischemia in a rabbit model.
- Vasodilation appears to be a key mechanism for enhancing flap survival in this context.
- Antithrombotic properties alone may not be sufficient to guarantee flap survival post-ischemia.